Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449018 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02449018 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 92 participants.
The verdict
NCT02449018, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
Interventions
- DRUG Placebo
- DRUG QBW251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2017-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02449018
The ClinicalTrials.gov registry entry for NCT02449018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02449018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02449018 about?
NCT02449018 is a clinical study titled "A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251". To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
What is the current status of trial NCT02449018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2015-04-30. Estimated completion is 2017-01-23.
What interventions are being tested in trial NCT02449018?
The interventions under investigation include: Placebo (DRUG), QBW251 (DRUG).
Who is sponsoring clinical trial NCT02449018?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.